ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: SA-PO301

CYP24A1 Activity Associates with Phenotypic Traits in Idiopathic Hypercalciuria

Session Information

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical


  • Fuster, Daniel G., Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
  • Bargagli, Matteo, Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
  • Bonny, Olivier, Service of Nephrology, Lausanne University Hospital, Lausanne, Switzerland

Hypercalciuria is the most frequent abnormality in kidney stone formers. The underlying mechanisms remain unknown in most cases, hence the designation “idiopathic hypercalciuria”. We hypothesized that the Vitamin D-inactivating enzyme CYP24A1 contributes to the pathogenesis of hypercalciuria in kidney stone formers.


We conducted association analyses between CYP24A1 activity, estimated by the Vitamin D metabolite diagnostic ratio (25(OH)-/24,25 (OH)2 Vitamin D3 ratio; VMDR), and the phenotype of participants in two observational cohorts of kidney stone formers, the Swiss Kidney Stone Cohort and the Bern Kidney Stone Registry. Linear and logistic regression models adjusted for multiple confounders, including plasma 25(OH) Vitamin D3, were applied. Plasma 25(OH)- and 24,25 (OH)2 Vitamin D3 were quantified using an established, highly sensitive and specific LC-MS/MS assay.


In total, 974 participants were included in the analysis. After multivariable adjustment, a higher VMDR (i.e. lower CYP24A1 activity) was associated with higher total plasma calcium (β 0.07; 95% CI 0.01, 0.14; p = 0.02), ionized calcium (β 0.11; 95% CI 0.03, 0.18; p < 0.01) and absolute and fractional excretion of urinary calcium (β 0.06; 95% CI 0.00, 0.11; p = 0.04 and β 0.10; 95% CI 0.04, 0.16; p < 0.01, respectively). A higher VMDR was further associated with an increased risk of forming stones composed of calcium oxalate dihydrate (Odds ratio 1.64; 95% CI 1.22, 2.35; p < 0.01) and a reduced bone mineral density at the femoral neck (β -0.07; 95% CI 0.14, -0.01; p = 0.04). VMDR was not associated with plasma or urinary phosphate, 1,25 (OH)2 Vitamin D3 or parathyroid hormone.


Our study reveals that CYP24A1 activity is associated with traits previously linked to idiopathic hypercalciuria.